• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Lupus Anticoagulant Testing

        互联网

        752
        Antiphospholipid antibodies are a heterogenous group of autoantibodies directed against glycoproteins in concert with anionic phospholipids. In clinical laboratory practice, antiphospholipid antibody evaluations usually consist of a combination of the following: anticardiolipin antibody assay, anti-beta 2 glycoprotein I assay, and at least two lupus anticoagulant assays with an appropriate confirmatory test. Lupus anticoagulants produce their laboratory effect by prolonging recalcification times in assays within which phospholipid content is limited. Although many assays are available, all are based on the fundamental principle of demonstrating normalization of prolonged recalcification times with the addition of exogenous phospholipid. The antibody specificity of an individual lupus anticoagulant is difficult or impossible to determine; however a small proportion do demonstrate avidity for selected proteins such as prothrombin or beta 2 glycoprotein I. The mechanism by which these antibodies cause their clinical manifestations remains unknown; however their relationship to increased risk of thrombosis, pregnancy loss, and autoimmune thrombocytopenia is undoubted. There is no correlation between the “strength” of lupus anticoagulants and the level of thrombotic risk; thus it is important to identify both “weak” and “strong” lupus anticoagulants.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序